Ifosfamide for men with advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial is studying whether the chemotherapy drug ifosfamide (given with mesna to protect the bladder) can help men whose prostate cancer has spread and is no longer controlled by hormone therapy. It is for men who have already tried the chemotherapy docetaxel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 19 or older
- Your prostate cancer has spread to other parts of the body and is resistant to hormone therapy
- You have already been treated with the chemotherapy drug docetaxel
- You are able to get around and take care of yourself (ECOG performance status 0, 1, or 2)
- You have measurable disease that can be seen on scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
This trial tests a new drug that targets low-oxygen areas in tumors, combined with standard hormone therapy, for men whose prostate cancer has spread and stopped responding to first-line hormone therapy. It may be an option if you've already had one hormone therapy and possibly chemotherapy, or if you can't have chemotherapy.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Hear when a new Prostatic Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.